Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers.
Therapeutic inhibition of the mammalian target of rapamycin (mTOR) has recently demonstrated a 30% to 40% response rate in patients with relapsed mantle cell lymphoma (MCL).(1,2) However, the exact mechanisms underlying this clinically significant response rate remain poorly understood. Here, we discuss the potential molecular mechanisms underlying this activity, and how to improve the therapeutic value of mTOR inhibitors by combining them with other agents that may target different molecular pathways.
Younes
Anas
A
Department of Lymphoma/Myeloma, M.D.Anderson Cancer Center, Houston, Texas 77030, USA. ayounes@mdanderson.org
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D011494:Protein Kinases / Q000378:metabolism*; D058570:TOR Serine-Threonine Kinases
D000970:Antineoplastic Agents; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases